Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTRENASDAQ:LFSTNASDAQ:PINCNASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTREFortrea$4.16+2.3%$6.01$3.99▼$28.41$376.03M2.151.80 million shs1.57 million shsLFSTLifeStance Health Group$6.06+10.3%$6.39$4.64▼$8.61$2.35B1.31.59 million shs3.31 million shsPINCPremier$23.04-0.1%$20.56$17.23▼$23.62$1.90B0.541.25 million shs1.75 million shsPRTAProthena$4.57-30.6%$9.54$4.46▼$25.42$245.72M0.11638,950 shs8.75 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTREFortrea0.00%-8.76%-31.42%-72.40%-84.11%LFSTLifeStance Health Group0.00%-5.99%-15.93%-26.95%-3.68%PINCPremier0.00%-0.22%+14.78%+26.63%+21.43%PRTAProthena0.00%-11.08%-32.16%-55.02%-67.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTREFortrea3.2764 of 5 stars3.92.00.00.02.30.82.5LFSTLifeStance Health Group2.6177 of 5 stars3.42.00.00.03.42.50.6PINCPremier2.0216 of 5 stars1.02.02.50.03.62.51.9PRTAProthena3.5333 of 5 stars4.23.00.00.03.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTREFortrea 1.86Reduce$15.00261.01% UpsideLFSTLifeStance Health Group 2.83Moderate Buy$8.5040.38% UpsidePINCPremier 2.00Hold$22.20-3.64% DownsidePRTAProthena 2.44Hold$31.50590.03% UpsideCurrent Analyst Ratings BreakdownLatest PINC, LFST, PRTA, and FTRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.505/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/22/2025FTREFortreaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/21/2025PINCPremierPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.00 ➝ $24.005/15/2025PINCPremierRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.00 ➝ $22.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTREFortrea$2.69B0.14$0.66 per share6.28$19.58 per share0.21LFSTLifeStance Health Group$1.28B1.83N/AN/A$3.77 per share1.61PINCPremier$1.26B1.51$4.43 per share5.20$18.81 per share1.22PRTAProthena$137.94M1.78N/AN/A$10.46 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTREFortrea-$3.40M-$8.79N/A3.251.78-10.99%2.00%0.80%8/11/2025 (Estimated)LFSTLifeStance Health Group-$186.26M-$0.10N/AN/AN/A-7.90%-6.66%-4.51%8/14/2025 (Estimated)PINCPremier$119.54M$0.57N/A17.32N/A-0.40%9.41%5.38%N/APRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/14/2025 (Estimated)Latest PINC, LFST, PRTA, and FTRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025FTREFortrea-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million3/3/2025Q4 2024FTREFortrea$0.36$0.18-$0.18-$0.68$703.22 million$697.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTREFortreaN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/APINCPremier$0.843.65%+2.50%147.37%N/APRTAProthenaN/AN/AN/AN/AN/ALatest PINC, LFST, PRTA, and FTRE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/24/2025PINCPremierquarterly$0.214.2%5/30/20256/1/20256/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTREFortrea0.741.181.18LFSTLifeStance Health Group0.191.321.32PINCPremierN/A0.830.83PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTREFortreaN/ALFSTLifeStance Health Group85.50%PINCPremier74.41%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipFTREFortrea0.12%LFSTLifeStance Health Group3.20%PINCPremier0.96%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTREFortrea18,00090.50 million89.59 millionOptionableLFSTLifeStance Health Group6,640388.88 million357.39 millionOptionablePINCPremier2,60082.34 million90.43 millionOptionablePRTAProthena13053.83 million38.64 millionOptionablePINC, LFST, PRTA, and FTRE HeadlinesRecent News About These CompaniesJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 27 at 1:28 PM | insidermonkey.comProthena's Late-Stage Study for AL Amyloidosis Fails, Stock DownMay 27 at 11:21 AM | zacks.comWhy Is Prothena Stock Trading Lower On Tuesday?May 27 at 7:43 AM | benzinga.comProthena slumps on Phase III birtamimab missMay 26 at 7:10 PM | thepharmaletter.comDeutsche Bank AG Purchases 63,512 Shares of Prothena Co. plc (NASDAQ:PRTA)May 26 at 3:34 AM | marketbeat.comProthena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary EndpointMay 23, 2025 | businesswire.comBNP Paribas Financial Markets Purchases 41,541 Shares of Prothena Co. plc (NASDAQ:PRTA)May 22, 2025 | marketbeat.comBalyasny Asset Management L.P. Makes New $527,000 Investment in Prothena Co. plc (NASDAQ:PRTA)May 18, 2025 | marketbeat.comCantor Fitzgerald Upgrades Prothena (NASDAQ:PRTA) to "Strong-Buy"May 17, 2025 | marketbeat.comProsight Management LP Sells 65,345 Shares of Prothena Co. plc (NASDAQ:PRTA)May 17, 2025 | marketbeat.comProthena Shareholders Approve Key Amendments at AGMMay 16, 2025 | tipranks.comCantor Fitzgerald Expects Increased Earnings for ProthenaMay 16, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Issues Quarterly Earnings ResultsMay 12, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Receives "Buy" Rating from Chardan CapitalMay 11, 2025 | marketbeat.comProthena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025May 9, 2025 | zacks.comProthena Corporation plc: Prothena Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deProthena Corp (PRTA) Sees Price Target Reduction by HC Wainwright & Co. | PRTA Stock NewsMay 9, 2025 | gurufocus.comProthena Corp (PRTA) Sees Price Target Adjusted by JMP Securities | PRTA Stock NewsMay 9, 2025 | gurufocus.comIs Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | msn.comProthena Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finance.yahoo.com3PRTA : Beyond The Numbers: 7 Analysts Discuss Prothena Corp StockMay 9, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePINC, LFST, PRTA, and FTRE Company DescriptionsFortrea NASDAQ:FTRE$4.16 +0.10 (+2.34%) Closing price 03:59 PM EasternExtended Trading$4.13 -0.03 (-0.70%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.LifeStance Health Group NASDAQ:LFST$6.06 +0.57 (+10.29%) Closing price 03:59 PM EasternExtended Trading$6.06 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.Premier NASDAQ:PINC$23.04 -0.02 (-0.10%) Closing price 03:59 PM EasternExtended Trading$23.04 0.00 (-0.01%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services; and STOCKD, an e-commerce platform, as well as direct sourcing business; SaaS informatics products; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company was incorporated in 2013 and is based in Charlotte, North Carolina.Prothena NASDAQ:PRTA$4.57 -2.02 (-30.62%) Closing price 03:59 PM EasternExtended Trading$4.58 +0.01 (+0.33%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
